CINECA IRIS Institutional Research Information System

BERTOTTI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.354
EU - Europa 8.435
AS - Asia 8.266
OC - Oceania 239
SA - Sud America 202
AF - Africa 71
Continente sconosciuto - Info sul continente non disponibili 13
Totale 29.580
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.958
CN - Cina 5.031
IT - Italia 2.426
GB - Regno Unito 1.105
DE - Germania 1.009
JP - Giappone 952
FR - Francia 633
SE - Svezia 453
ES - Italia 446
SG - Singapore 418
IN - India 410
IE - Irlanda 393
HK - Hong Kong 352
FI - Finlandia 333
CA - Canada 332
KR - Corea 307
NL - Olanda 256
PL - Polonia 180
AU - Australia 179
CH - Svizzera 178
TW - Taiwan 170
BE - Belgio 160
AT - Austria 140
BR - Brasile 138
UA - Ucraina 138
TR - Turchia 132
VN - Vietnam 103
GR - Grecia 82
RU - Federazione Russa 82
IL - Israele 79
PT - Portogallo 73
DK - Danimarca 63
TH - Thailandia 61
NZ - Nuova Zelanda 60
CZ - Repubblica Ceca 57
MX - Messico 55
RO - Romania 54
IR - Iran 46
NO - Norvegia 42
HU - Ungheria 31
ID - Indonesia 29
SA - Arabia Saudita 29
MY - Malesia 27
PK - Pakistan 25
CO - Colombia 21
EG - Egitto 20
CL - Cile 18
AR - Argentina 15
ZA - Sudafrica 15
HR - Croazia 14
LB - Libano 14
SK - Slovacchia (Repubblica Slovacca) 13
NG - Nigeria 12
LT - Lituania 11
MO - Macao, regione amministrativa speciale della Cina 11
AM - Armenia 10
JO - Giordania 10
PH - Filippine 10
EE - Estonia 8
RS - Serbia 8
SI - Slovenia 8
KE - Kenya 7
LU - Lussemburgo 7
SN - Senegal 7
AP - ???statistics.table.value.countryCode.AP??? 6
BA - Bosnia-Erzegovina 6
AE - Emirati Arabi Uniti 5
CY - Cipro 5
EC - Ecuador 5
EU - Europa 5
IS - Islanda 5
KZ - Kazakistan 5
QA - Qatar 5
TN - Tunisia 5
UZ - Uzbekistan 5
CU - Cuba 4
GE - Georgia 4
OM - Oman 4
PE - Perù 4
BG - Bulgaria 3
BY - Bielorussia 3
IM - Isola di Man 3
KH - Cambogia 3
LK - Sri Lanka 3
MK - Macedonia 3
MT - Malta 3
A1 - Anonimo 2
AL - Albania 2
DM - Dominica 2
DZ - Algeria 2
MD - Moldavia 2
PA - Panama 2
BN - Brunei Darussalam 1
GH - Ghana 1
LV - Lettonia 1
MC - Monaco 1
PR - Porto Rico 1
TZ - Tanzania 1
UG - Uganda 1
UY - Uruguay 1
Totale 29.580
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.066
Beijing 987
Chandler 826
Fairfield 798
Shanghai 771
Houston 604
Redwood City 487
Ashburn 449
Seattle 429
Woodbridge 407
Cambridge 402
Guangzhou 380
Dublin 359
Wilmington 355
Torino 339
Tokyo 277
Singapore 263
Nanjing 235
New York 199
Milan 198
Turin 189
Dearborn 160
Lappeenranta 151
Hangzhou 149
Pisa 148
Nyköping 142
Wuhan 131
San Diego 125
London 116
Boston 109
Jacksonville 109
Warsaw 109
Los Angeles 108
Taipei 107
Vienna 107
Villeurbanne 106
Rome 104
Zhengzhou 103
Princeton 99
Chengdu 94
Medford 94
Toronto 86
Duncan 81
Central 80
Changsha 79
Fremont 79
Paris 79
San Francisco 75
Munich 74
Boardman 71
Barcelona 68
Brussels 64
Central District 64
Ottawa 64
Shenyang 64
Amsterdam 62
Chicago 60
Chongqing 60
Seoul 60
Berlin 58
Dong Ket 58
Jinan 58
Madrid 57
Tianjin 57
Manchester 55
Nanchang 52
Genoa 47
Helsinki 45
Xian 42
Carrara 41
Hefei 41
Fuzhou 40
Mumbai 39
Heidelberg 38
Sydney 38
Norwalk 37
Philadelphia 37
Dallas 36
Shenzhen 36
Istanbul 35
San Jose 35
Hong Kong 34
Santa Clara 34
Bangkok 32
Bengaluru 31
Florence 31
Naples 31
São Paulo 31
Toulouse 31
Phoenix 30
Vancouver 30
Hyderabad 29
Melbourne 29
San Mateo 29
Nashville 28
Atlanta 27
Harbin 27
Pittsburgh 27
Belfast 26
Moscow 26
Totale 15.206
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 5.049
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. 4.990
Stromal contribution to the colorectal cancer transcriptome. 1.838
Adaptive mutability of colorectal cancers in response to targeted therapies 1.710
MET signalling: principles and functions in development, organ regeneration and cancer. 1.520
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.134
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. 699
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 654
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 627
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 562
MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. 379
The genomic landscape of response to EGFR blockade in colorectal cancer 338
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer 326
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 322
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. 314
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 304
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts 281
Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer 274
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 268
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 247
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 246
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment 239
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 238
Only a subset of Met-activated pathways are required to sustain oncogene addiction 238
Genetic and expression analysis of MET, MACC1 and HGF in metastatic colorectal cancer: Response to Met inhibition in patient xenografts and pathological correlations 228
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype 221
Met-driven invasive growth involves transcriptional regulation of Arhgap12 219
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 211
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. 209
Inhibition of Src impairs the growth of met-addicted gastric tumors. 206
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 199
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 184
Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals 179
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. 176
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts 173
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. 170
A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy 170
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 164
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors 163
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga 158
NOTCH3 SIGNALING REGULATES MUSASHI-1 EXPRESSION IN METASTATIC COLORECTAL CANCER CELLS. 156
A diphtheria toxin resistance marker for in vitro and in vivo selection of stably transduced human cells 155
Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma 150
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth 149
Semalytics: a semantic analytics platform for the exploration of distributed and heterogeneous cancer data in translational research 149
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 148
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 145
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 144
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. 138
PDX-MI: Minimal information for patient-derived tumor xenograft models 130
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 129
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 117
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 115
Effective drug combinations in breast, colon and pancreatic cancer cells 112
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas 108
One tool to find them all: A case of data integration and querying in a distributed LIMS platform 103
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases 102
Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer 100
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 94
A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. 90
MET SIGNALING REGULATES GROWTH, REPOPULATING POTENTIAL AND BASAL CELL-FATE COMMITMENT OF MAMMARY LUMINAL PROGENITORS: IMPLICATIONS FOR BASAL-LIKE BREAST CANCER. 88
HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity 87
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 84
Implementing systems modelling and molecular imaging to predict the efficacy of BCL-2 inhibition in colorectal cancer patient-derived xenograft models 80
Met as a potential therapeutic target in basal-like breast cancer: An in vivo approach in a stem-cell perspective 78
beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. 75
Met as a potential therapeutic target in basal-like breast cancer 71
Animal research: Temper Italy's strict lab-animal law. 70
Derivation and charaterization of cancer initialling cells representative of metastatic colorectal cancer genetic heterogeneity 69
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. 68
Identification and pre-clinical validation of surrogate soluble biomarkers correlating with therapeutic response to met inhibition 68
Tyrosine kinase signal specificity: lessons from the HGF receptor. 67
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma 66
Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin 64
Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: Six degrees of separation 64
LAS: A Bio-Clinical Integrated Laboratory Information System for Translational Data Management 64
Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of nedd8 and egfr pathways 61
Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling 53
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer 49
Interrogating open issues in cancer precision medicine with patient-derived xenografts 44
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells 43
The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization 42
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT) 38
From Bench to Bedside: Does Preclinical Practice in Translational Oncology Need Some Rebuilding? 36
CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system 34
LAS: A Software Platform to Support Oncological Data Management 30
Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity 26
Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer 25
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer 24
Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer 20
EGAsubmitter: A software to automate submission of nucleic acid sequencing data to the European Genome-phenome Archive 14
Genome-wide CRISPR screens reveal Hippo pathway activation as a resistance mechanism in BRAF mutant colon cancer 14
Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies 14
PO-050 A molecularly annotated platform of pdx-derived cell lines mirrors the genomic landscape of colorectal cancer 11
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 11
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 9
Abstract LB-299: A comprehensive platform of patient-derived xenografts and matched cell lines mirrors the genomic landscape of colorectal cancer 8
Abstract B33: The oligoclonal antibody MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations 8
PhyliCS: a Python library to explore scCNA data and quantify spatial tumor heterogeneity 8
XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients 5
Totale 30.151
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.462
article - articoli 0
book - libri 0
conference - conferenze 2.869
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.331
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.106 0 0 256 457 257 450 321 290 350 295 232 198
2020/20215.202 187 299 497 509 469 487 547 325 463 460 423 536
2021/20225.203 495 490 466 507 385 390 448 404 405 284 523 406
2022/20234.222 328 340 245 405 325 590 310 397 440 219 306 317
2023/20244.918 381 405 312 432 359 399 407 415 154 534 645 475
2024/20251.003 373 443 187 0 0 0 0 0 0 0 0 0
Totale 30.162